Litcius/Paper detail

LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Hacı Mehmet Türk, İ. Çiçin, Dmitry Bentsion, Oleg Gladkov, Philip R. Clingan, Virote Sriuranpong, Naiyer A. Rizvi, S. Li, S. Lee, Giuseppe Gullo, Israel Lowy, Petra Rietschel

2020Annals of Oncology27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineLung cancerPopulationGastroenterologyInterim analysisProgression-free survivalnon-small cell lung cancer (NSCLC)ChemotherapyOncologyRandomized controlled trialEnvironmental healthA549 cellCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesLung Cancer Treatments and Mutations
LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% | Litcius